Vertex plans to grow epilepsy drug trial

By Eric Convey, Boston Business Journal

Vertex gets European committee nod [May 25, 2012]

Boehringer Ingelheim announces diabetes trial data [May 24, 2012]

Aveo starts Phase 1 trial of solid tumor treatment [May 23, 2012]

Alnylam gets RNAi patent from Plant Bioscience [May 23, 2012]

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) said it will conduct a broader trial of a potential drug against epilepsy following positive results in a Phase 2 study.

The Cambridge pharmaceutical company said VX-765 proved as safe as a placebo and also met certain clinical benchmarks in a study involving 60 patients with epilepsy that had proved stubborn against other treatments.

In a prepared statement, Vertex Chief Scientific Officer Peter Mueller said: “The use of anti-inflammatory medicines is a completely new way to approach the treatment of epilepsy, and this study was an important first step toward understanding whether VX-765 could help people with this disease.”

A broader trial could begin in fall 2011, the company said.

The company confirmed in January that it is planning to move to Boston’s Fan Pier on the South Boston waterfront.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.